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In October 2007, the Japanese Health Authority directed that precautions be added to anti-
depressants (ADs) labelling regarding suicide risk among young people.
This study evaluates the impact of the labelling change on AD prescriptions and Japa-
nese adolescent suicide rates.
Methods
We compared AD prescription rates per 100,000 population as a primary outcome. The
intervention group comprised adolescents (10–24 years), while the control group comprised
adults (25–64 years). We defined the pre-intervention period as January 2005 to October
2007 and post-intervention as November 2007 to February 2013. Monthly prescription rate
data from a commercial claims database were triangulated with annual suicide rates in
Japan. We performed segmented regression analysis for the prescription rates, using a
quasi-Poisson model, and tested for level and trend changes.
Results
The commercial claims database included 152,686 adolescents and 195,251 adults during
the pre-intervention period and 846,367 adolescents and 1,352,453 adults during post-inter-
vention. Post-intervention, the overall AD prescription rates decreased only in adult males
(-95.8 prescription per 100,000) but increased in all other groups. The mean annual suicide
rate increased in adolescent males (+1.5 suicides per 100,000) but decreased in all other
groups. Overall, the upward trend became moderate or inverse in all groups post-interven-
tion but with a large difference between males and females. The suicide rates rose slightly in
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adolescents but began declining in adults a year post-intervention. In females, changes in
level, trend, and suicide rates were very small in both adolescents and adults.
Conclusions
Contrary to expectations, the mean prescription rates only decreased in adult males, but not
in adolescents, regardless of gender. Downward level and trend change were clearly
observed in adult males but not in adolescents, the original target of the updated warning.
There were no clear temporal associations between suicide rates and the labelling change
in either group.
Introduction
While antidepressants (ADs) can improve depression, several studies have shown that treat-
ment with ADs may increase suicide risk in the young population [1,2]. From 2003 to 2007,
the United States Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) added strong warnings to AD product information sheets [3,4]. The FDA stipulated
that the general warnings about suicide on all AD package inserts should be modified to spec-
ify the risk of suicide by paediatric and adolescent patients under 25 years old. This measure
was taken in response to an FDA meta-analysis that demonstrated a higher relative risk of sui-
cidality in young people taking ADs compared with those who were given a placebo [5]. In
Europe, the precaution regarding suicidal behaviour amongst young people was also added to
AD labelling. In response to these regulatory actions, on 31 October 2007, the Japanese Minis-
try of Health, Labour and Welfare (MHLW) ordered all AD manufacturers to include unified
warnings against AD use in young people in the ‘Precautions’ section of package inserts [6].
ADs that entered the market after the intervention also included these warnings in their pack-
age inserts.
Several studies in the US, EU, and Australia have already demonstrated that a decrease in
rates of AD prescription in adolescents only partially decrease or increase in suicidal behaviour
[7–13]. Moreover, spill-over effects on prescription rates were seen in the non-targeted older
adult population [7,10,14]. On the other hand, regarding the impact of the same intervention
in Japan, one report by the Pharmaceuticals and Medical Devices Agency (PMDA) analysed
the Japan Medical Data Center Claims database (JMDC database) [15] and demonstrated that
the mean monthly number of paroxetine users aged under 18 years decreased from 13 to 10
users following the labelling change in October 2007. However, it is not known whether these
changes in prescription rates resulted in changes to adolescent suicide rates. Therefore, assess-
ing the impact of the intervention is important for successful implementation of future risk
minimisation measures.
This study aimed to measure the impact of the labelling change in October 2007 on AD pre-
scription rates and suicides rates among young people aged 10 to 24 years compared with the
adult population (25 to 74 years old, control group). The objectives are (1) to analyse the trends
of AD prescription rates both before and after the intervention, (2) to evaluate whether the
effect varies by gender and drug class, and (3) to examine the potential impacts on suicide
rates. The prescription rate was analysed as a process indicator and suicide rate as an outcome
indicator for assessing, in accordance with the definition of the EU Guideline on Good Phar-
macovigilance Practices (GVP) [16].
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Materials and methods
Study design
This study comprised a retrospective review of medical records from the JMDC database and
Japan’s annual Vital Statistics records by MHLW. The prescription trends were analysed by
interrupted time series (ITS). ITS is the strongest design for evaluating longitudinal effects of
population-level interventions controlling for prior trends in the outcome [17,18]. To have
sufficient power to estimate the parameters, it is essential to have at least 8 time points before
and after the intervention in general [19]. When ITS is performed for fewer observations, such
as when assessing the effectiveness of interventions immediately after intervention, it requires
the analysis of pre-intervention data and stronger counterfactual assumptions or the applica-
tion of other methods such as sequential monitoring methods [19]. Therefore, the annual sui-
cide rates were not analysed by segmented regression because there were only 3 time points
before the intervention and 9 time points in total; however, we compared the mean values of
the pre- and post-intervention periods.
Data sources
Data on AD prescription were obtained from the JMDC database [20], the largest claims data-
base in Japan comprising medical and pharmacy claims data of multiple company employees
and their family members from 2005 [21]. The JMDC database does not include data regard-
ing race or ethnicity, but it was assumed that the data are composed mainly of Japanese people
as the percentage of foreigners in the total workforce ranged from 0.8% to 1.1% from 2008 to
2013. The database is completely anonymised and standardised. Once retired, members are
insured by other insurance schemes; therefore, the JMDC database only includes data of peo-
ple aged 0–74 years old. Since the JMDC database is based on information from insurance
reimbursements, it may not include data regarding all deaths, such as deaths from suicides
outside of medical institutions. Therefore, information about suicides was obtained from
other sources [21,22]. Annual suicide counts, rates, and data of the population denominator of
the whole country were taken from the Japanese Ministry of Health, Labour and Welfare Vital
Statistics (Vital statistics) [23].
Intervention and investigation period
The pre-intervention period comprises 34 months (January 2005 to October 2007). Since
another class-level labelling change for precautions for paediatric use was directed by the
PMDA in March 2013 [24], the post-intervention period was defined as November 2007 to
February 2013, spanning 65 months. Although the PMDA’s pilot study demonstrated a
decrease in prescription of paroxetine three months after the labelling change [15], there was
no clear time lag between change in labelling and change in prescription rate. Therefore, no
time lag was included in the final model. For annual suicide rates, the pre-intervention period
was defined from 2005 to 2007, while post-intervention was defined from 2008 to 2013.
Study population
The target population for the warning is adolescents up to 24 years old. The intervention
group was defined as individuals aged 10 to 24 years for the following reasons. Firstly, the
WHO definition of adolescents is individuals in the 10–19-year age group [25]. Secondly, ADs
are unlikely to be prescribed to infants and very young children. To improve the validity of the
results and examine the spill-over effect on non-targeted groups, people aged 25 to 74 years
were included as a control group. For analysing prescription rates, the age of patients at time
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of prescription was calculated on a yearly basis. Each individual was allocated to a certain
group based on the time of enrolment in the JMDC database.
Outcome measures
While the labelling change began with paroxetine (selective serotonin reuptake inhibitor,
SSRI) and the group of serotonin-norepinephrine reuptake inhibitors (SNRIs) and was then
expanded to all ADs, and because both SSRI and SNRI are recommended as a first-line treat-
ment for mild and moderate depression, we separately investigated two drug categories: ‘SSRIs
and SNRIs (SSRI/SNRI)’ and ‘others’ in view of the possibility that the prescribing conditions
for patients using SSRI or SNRI and patients using other ADs may differ. AD prescriptions for
depression were identified using Anatomical Therapeutic Chemical (ATC) codes (N06: antide-
pressant). We further stratified AD prescription rates by gender. The drug codes are shown in
S1 Table.
As the background trend of depression rates may change over time, we calculated the
monthly rate of people with ‘depression’ (F32.x or F33.x) in the JMDC database’s ‘main dis-
eases’ section as depression rates. In addition, some ADs had indications other than depres-
sion. Therefore, to avoid selection bias, the number of all enrolees in a month was used as a
population denominator.
Suicide rates of the intervention and control groups were calculated from the vital statistics.
To remain consistent with the JMDC database, we calculated the rates from the data of adoles-
cents aged 10–24 years as an intervention group and adults aged 25–74 years as a control
group.
The number of completed suicides was extracted from the pre-defined category ‘suicides’ as
a cause of death, as was the number of individuals in each group. Annual suicide rates were
converted per 100,000 people.
Modelling of segmented regression
A Poisson distribution was used to estimate the monthly number of AD prescriptions.
Monthly population denominator data of the JMDC database were included as an offset vari-
able to convert the number into a prescription rate to adjust for an increasing number of enro-
lees over time.
Bernal et al. provide examples of basic impact models for ITS [18]. The ‘level and trend
change’ model was applied based on the hypothesis that the prescription rate increased in line
with an increase in the consultation rate for depression. In terms of the trend, the prescription
rate rose due to the decreasing stigma of psychiatric disorders, the government’s awareness
campaign, and the introduction of new drugs such as SSRIs and SNRIs without a change in
labelling (counterfactual) [26,27]. After the labelling change, two hypotheses were made. First,
in terms of the actual effect of the labelling change, we hypothesised that the upward trend
would be moderate or reversed because physicians would become more careful about adminis-
tering ADs to young people. In terms of prescription level, the total number of prescriptions
(level) would drop as physicians would avoid prescribing to a high-risk population. We
hypothesised similar trends as previous studies conducted in other countries [7–13].
In the present study, segmented regression was used to estimate the modelled prescription
rates. The following Poisson model (‘level and trend change’ model) was applied [17].
Yt ¼ b0 þ b1 � timet þ b2 � interventiont þ b3 � time after interventionþ ET
Yt represents the log prescription rate at timet (log (number of people with ADs / denomi-
nator)), where time is a continuous variable to express time elapsed from the start of the
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observation period; interventiont is a dummy variable indicating the pre-intervention period
(coded 0) or post-intervention period (coded 1); and ‘time after intervention’ is a counted
number of months after the intervention at time t. β0 also represents the baseline level of the
log prescription rate at time = 0; β1 estimates the underlying pre-intervention (baseline) trend;
β2 estimates the level change in log prescription rate following the intervention; and β3 repre-
sents the trend change in log prescription rate following the intervention. The trend of post-
intervention is calculated as the sum of β1 and β3. ET represents the error term.
The relevant data for analysis were extracted from the full dataset of the JMDC database
using SAS ver.9.4 and analysed using Stata IC ver.15. P values< 0.05 were considered to be
statistically significant.
Sensitivity analysis
Since the depression rate may be a time-variant factor, the number of people with depression
was considered to be included in the regression models as an explanatory variable. It is impor-
tant to check autocorrelations (serial correlations) when conducting ITS because they are
assumed to be independent of observations in the standard regression model [17–19]. In the
present study, autocorrelation was investigated using correlograms and a Q test for the Ljung-
Box test. In addition, seasonal autocorrelation (seasonality) was adjusted by Fourier terms
using pairs of sine-cosine [28]. The adjusted models were compared with the unadjusted mod-
els using the likelihood ratio test and the Akaike information criterion (AIC) [29].
Ethical considerations
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine eth-
ics committee (ref.4733/RR/9483). The JMDC database has already been standardised with de-
identified individual medical information. As only count data were used, there was no direct
patient contact for the data collection and analysis process; therefore, informed consent for the
study was not required to be obtained from the patients.
Results
Descriptive analysis
During the pre-intervention period, 152,686 individuals aged 10–24 years (adolescents) and
195,251 individuals aged 25–74 years (adults) were included. During the post-intervention
period, 846,367 adolescents and 1,352,453 adults were included. The characteristics of the
cohorts of each period are shown in Table 1. Background information, such as the proportion
of each gender, diagnosis of depression, and the proportion and other frequent psychiatric
comorbidities, were similar between pre- and post-intervention periods for both intervention
and control groups.
In the intervention group, the mean monthly AD prescription rate increased overall, and
for SSRIs and SNRIs, it increased in both males and females, although the increase was more
pronounced among males. The mean annual suicide rates increased in male adolescents. Con-
versely, among adults (control group), the mean prescription rates for AD decreased among
men but not among women, whereas the mean suicide rates decreased for both genders
(Table 2).
The overall prescription rates were lower than the sum of SSRI/SNRI and other ADs during
the investigation period. This result indicated that a substantial number of patients were pre-
scribed both SSRIs or SNRIs, and other ADs (Table 2).
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Modelling of segmented regression
Since the mean was not equal to the variance of the dataset, the scale parameter was added to
the model, allowing over-dispersion (quasi-Poisson model). The final models were adjusted
for seasonality using the likelihood ratio test, with the AIC showing improvement in the sea-
sonally adjusted models. After adjusting for seasonality, no notable change was observed in the
rate ratio and p-values compared with the unadjusted results. The correlograms and Q test
showed the presence of an autocorrelation and partial autocorrelation even after adjusting for
seasonality. Since the generalised linear model of the Poisson regression used a maximum like-
lihood estimation, the autocorrelation of data did not affect the results. Although autocorrela-
tion was present in the Poisson regression model, consistent estimates may be obtained using
the quasi-likelihood method [30]. The models were not adjusted for depression rates because
the correlation coefficient between the number and rates of AD prescriptions and depression
indicated strong correlation.
Overall change in prescription and depression rates
When adolescents and adults were compared, a suppressive trend change was observed in
both groups after the labelling change. However, the change in prescription level was more







Male 86,014 (56.3) 463,273 (54.7)
Female 66,672 (43.7) 383,094 (45.3)
Mean age (SD) at the middle of the period (2006 for pre-
intervention, 2010 for post-intervention period)
12.9 (5.11) 16.9 (5.13)
Five most common comorbid psychiatric disorders (ICD-10 Codes)��
Depression (F32 or F33) 826 (0.54) 5795 (0.68)
Neurotic disorders (F48) 228 (0.15) 2080 (0.25)
Anxiety disorders (F41) 194 (0.13) 2383 (0.28)
Schizophrenia (F20) 153 (0.10) 2061 (0.24)
Somatoform disorders (F45) 141 (0.09) 1475 (0.17)
Adults (control group)
All 195,251 1,352,453
Male 115,527 (59.2) 755,115 (55.8)
Female 79,724 (40.8) 597,338 (44.2)
Mean age (SD) at the middle of the period (2006 for pre-
intervention, 2010 for post-intervention period)
41.7 (10.34) 43.6 (10.7)
Five most common comorbid psychiatric disorders (ICD-10 Codes)��
Depression (F32 or F33) 6416 (3.29) 45338 (3.35)
Anxiety disorders (F41) 1574 (0.81) 18687 (1.38)
Neurotic disorders (F48) 1222 (0.63) 13309 (0.98)
Somatoform disorders (F45) 992 (0.51) 10527 (0.78)
Schizophrenia (F20) 660 (0.34) 9723 (0.72)
�2006 for pre-intervention period. 2010 for post-intervention period.
��The ICD-10 codes described under ‘main diseases’ of the claims were calculated.
https://doi.org/10.1371/journal.pone.0243424.t001
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prominent in adult males (Figs 1 and 2, and Table 3) and less prominent in females (S1 and S2
Figs and Table 3). The depression rate showed an overall upward trend during the whole
investigation period, independent of age and gender in both the intervention and control
groups.
Table 2. Changes in mean monthly antidepressant prescription rates.
Pre-intervention period Post-intervention period Change
Adolescents (intervention group) Prescription rates per 100,000 mean SD min max mean SD min max
Male Any antidepressants 246.8 21.9 219.1 295.1 295.0 20.3 242.0 338.8 48.2
SSRI/SNRI 171.2 23.5 127.2 213.4 215.0 17.4 167.8 251.1 43.8
Other antidepressants 107.0 12.7 84.3 134.1 110.3 11.4 81.0 128.2 3.3
Female Any antidepressants 384.4 31.1 326.1 442.1 408.9 22.8 346.3 456.2 24.5
SSRI/SNRI 289.5 25.1 240.7 338.8 317.7 21.1 266.8 372.0 28.2
Other antidepressants 148.1 16.6 105.6 188.9 140.1 14.4 108.3 177.3 -7.9
Pre-intervention period Post-intervention period Change
Adults (control group) Prescription rates per 100,000 mean SD min max mean SD min max
Male Any antidepressants 1571.1 116.3 1307.9 1719.0 1475.4 91.2 1302.5 1700.2 -95.8
SSRI/SNRI 1177.1 116.9 941.2 1346.9 1144.1 78.9 994.6 1333.2 -33.0
Other antidepressants 773.0 35.0 659.8 812.2 643.7 46.0 563.4 787.1 -129.3
Female Any antidepressants 1257.0 48.2 1154.1 1335.7 1309.0 36.0 1229.0 1378.9 52.0
SSRI/SNRI 942.9 55.2 825.3 1024.8 1015.6 27.4 957.2 1060.7 72.6
Other antidepressants 489.0 21.2 454.2 532.8 489.7 20.6 449.8 529.0 0.7
SD: Standard Deviation; SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor.
https://doi.org/10.1371/journal.pone.0243424.t002
Fig 1. Changes in AD prescription and depression rates among male adolescents (10–24 years, intervention
group).
https://doi.org/10.1371/journal.pone.0243424.g001
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Change in prescription rates
Adolescents (10–24, intervention group). The results of the final model of the interven-
tion group are shown in Fig 1 and Table 3. Overall, the pre-intervention (baseline) trend in
prescription rate for any ADs increased by an average of 0.36% per month. After the interven-
tion, the level of AD prescriptions increased by 8.2%, and there was a downward change in the
trend (0.4% per month) after the intervention. Therefore, the total prescription rate decreased
by 0.04% per month after the labelling change.
A difference was observed in terms of gender and drug classes. In female adolescents
(Table 3 and S1 Fig), an upward trend was inverted after the labelling change. The level
increased but not to a statistically significant level. The same trend was also found in SSRIs/
SNRIs, but not in other ADs.
In male adolescents (Fig 2 and Table 3), a large level change (14.8% increase) was observed
in all ADs. A larger level change was found in other ADs (22.0% increase) with no significant
trend change, whereas the change in level did not significantly increase in SSRI/SNRI prescrip-
tions. However, the trend of SSRI/SNRI prescriptions changed from a sharp increase in the
pre-intervention period to moderate in the post-intervention period.
The gap between depression rates and prescription rates of all ADs widened after the label-
ling change, particularly in the intervention group; this indicated that the number of adoles-
cents who were depressed but were not administered ADs increased after the intervention.
Adults (25–74, control group). The results of the final model of the intervention group
are shown in Fig 2 and Table 3. However, the scatter plot of the prescription rates reported in
the control group demonstrated a slightly non-linear pattern during the investigation period.
Fig 2. Changes in AD prescription and depression rates among male adults (25–74 years, control group).
https://doi.org/10.1371/journal.pone.0243424.g002
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A considerable difference was observed between males and females. A significant decrease
in level was noted in males, due to the prescription of both SSRIs/SNRIs and other ADs (Fig 2
and Table 3). Fig 2 also shows an immediate decrease in prescription rates after the labelling
change in 2007. Furthermore, in 2009, an additional decrease in prescription rates was
observed in males. By contrast, no significant level change was observed in the prescription
rates of ADs in adult females (Table 3 and S2 Fig).
Change in suicide rates
During the study period, the suicide rate was remarkably higher in adult males than in other
groups. From 2005 to 2009, the suicide rates were stable in all groups, followed by a decrease
Table 3. Segmented analysis of antidepressant prescription rates after the labelling change.
Males Females
RR P-value 95%CI RR P-value 95%CI
Adolescents (10–24 years, intervention group)
Any antidepressants
Baseline level β0� 237.1 <0.001 217.9 258.0 352.1 <0.001 331.9 373.5
Baseline trend β1 1.002 0.255 0.998 1.006 1.005 <0.001 1.002 1.008
Change in level β2 1.148 0.001 1.060 1.242 1.021 0.456 0.966 1.079
Change in trend β3 0.998 0.321 0.994 1.002 0.994 <0.001 0.991 0.997
SSRI/SNRI
Baseline level β0� 147.7 <0.001 134.8 161.8 265.0 <0.001 247.6 283.7
Baseline trend β1 1.008 <0.001 1.004 1.013 1.005 0.002 1.002 1.008
Change in level β2 1.058 0.173 0.975 1.148 1.038 0.255 0.974 1.106
Change in trend β3 0.993 0.001 0.989 0.997 0.994 0.001 0.991 0.998
Other antidepressants
Baseline level β0� 115.5 <0.001 102.9 129.5 146.9 <0.001 133.2 162.0
Baseline trend β1 0.996 0.115 0.990 1.001 1.000 0.837 0.996 1.005
Change in level β2 1.220 0.001 1.087 1.368 1.051 0.314 0.954 1.156
Change in trend β3 1.002 0.529 0.996 1.007 0.996 0.108 0.991 1.001
Adults (25–74, control group)
Any antidepressants
Baseline level β0� 1393.5 <0.001 1321.1 1469.9 1213.8 <0.001 1172.3 1256.7
Baseline trend β1 1.007 <0.001 1.004 1.009 1.002 0.021 1.000 1.004
Change in level β2 0.854 <0.001 0.810 0.900 1.009 0.623 0.975 1.044
Change in trend β3 0.993 <0.001 0.990 0.995 0.998 0.033 0.996 1.000
SSRI/SNRI
Baseline level β0� 994.4 <0.001 938.7 0.0 866.2 <0.001 836.4 897.1
Baseline trend β1 1.009 <0.001 1.007 1.012 1.005 <0.001 1.003 1.006
Change in level β2 0.850 <0.001 0.804 0.899 0.995 0.772 0.962 1.029
Change in trend β3 0.990 <0.001 0.987 0.993 0.995 <0.001 0.994 0.997
(continued)
Baseline level β0� 732.4 <0.001 693.7 773.2 513.0 <0.001 488.4 538.9
Baseline trend β1 1.003 0.021 1.000 1.006 0.997 0.023 0.995 1.000
Change in level β2 0.830 <0.001 0.785 0.878 1.073 0.006 1.020 1.129
Change in trend β3 0.995 0.001 0.993 0.998 1.002 0.062 1.000 1.005
RR: Rate Ratio 95% CI: 95% confidence interval. All models were adjusted for seasonality.
�Converted to per 100,000 individuals.
https://doi.org/10.1371/journal.pone.0243424.t003
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in the rate of adult male suicide but not amongst other groups (Table 4 and Fig 3). After the
stratification by age group (10–14, 15–19, and 20–24 years), no group demonstrated a clear
downward trend. A slight increase was noted among males aged 20–24 years (S2 Table).
Discussion
Principal findings
Our findings demonstrated a prominent decrease in prescription rates amongst adult males,
who were not the main target of the added warnings. The prescription rate of all drug classes
decreased immediately after the intervention in adult males, whereas the level increased
slightly in adolescent males. In relation to trend change, in both the intervention and control
groups, the sharp upward trend in AD prescription, particularly in the SSRI/SNRI group,
became a decrease in incline in the upward trend or reversed to a downward trend after the
labelling change. However, the extent of trend change was similar. In addition, suicide rates in
Table 4. Changes in mean annual suicide rates.
Pre-intervention period Post-intervention period Change
Adolescents (intervention group) Suicide rates per 100,000 mean SD min max mean SD min max
Male 12.9 0.3 12.6 13.2 14.5 0.2 14.3 14.7 1.5
Female 6.8 0.2 6.6 6.9 6.5 0.7 5.8 7.3 -0.3
Adults (control group) Male 44.7 1.1 43.7 45.8 40.2 3.9 35.4 45.0 -4.5
Female 14.9 0.6 14.3 15.5 14.8 0.8 13.8 15.8 -0.1
https://doi.org/10.1371/journal.pone.0243424.t004
Fig 3. Changes in suicide rates.
https://doi.org/10.1371/journal.pone.0243424.g003
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young populations were steady after the labelling change, and such rates increased slightly in
2009.
The impact on prescription and suicide rates observed in this investigation exhibited both
similarities and differences to those reported in previous studies in other countries. Similar
additional warnings on labelling suppressed the increasing trend in prescription rates in tar-
geted and non-targeted populations in some studies [7,8,10,14]. In contrast, in Canada, SSRI
prescription increased in the young population from 2005 to 2009, after the addition of the
FDA warning. Of note, the approval of the paediatric indication of several SSRIs influenced
their increased use in Canada [31]. In Japan, although the efficacy and safety of SSRIs for pae-
diatric patients has not been established, the use of psychotropic medications, including ADs,
has considerably increased. That is, the number of patients aged<20 years seeking medical
treatment for psychiatric disorders increased from 95,000 in 2002 to 148,000 in 2008 [32]. A
retrospective study has shown that SSRIs were widely used not only for mood disorders but
also used off-label for other psychiatric disorders in children aged 7–18 years [33]. In addition,
26% of paediatric patients who used antipsychotics also used them in combination with ADs
[32]. In contrast to the ‘black box warning’ at the top of labelling in US packaging, the wording
of the precaution added to Japanese package inserts does not prohibit the use of ADs in young
individuals in Japan. Therefore, the interpretation of the precaution may vary between physi-
cians and countries depending on underlying trends of the incidence of depression and suicide
and on the languages in the labelling.
The present study demonstrated a slight decrease in the suicide rates of young populations
in 2009, which is when the global economic crisis occurred. However, the level of AD use
decreased in the US, and the increase in the rates of suicide attempts occurred simultaneously
with the decreased use of ADs in the young population after the addition of the warning by the
FDA [7,14]. In the present study, on the other hand, even the prescription rate rose after the
labelling change. It is unclear whether the increased suicide rate was a result of the increasing
rate of untreated depression. Although no decisive factor can explain why the level change was
more prominent in males in the control group, there were some potential factors related to the
obtained results. First, the main objective of the labelling change was to warn about the
increasing risk of suicide among adolescents. In addition, the revised wording for suicide risk
in the important precautions section is not specific to the young population but can be applica-
ble to all populations. Therefore, physicians are reminded of the risk not only to adolescents
but also to adults, and they also prescribed ADs to adult males more cautiously because this
group has the highest suicide rate in Japan. Second, another labelling change in 2009 warned
against the harmful behaviour and clinical worsening (including suicidal behaviour) related to
AD use in all populations [34,35], and this may have contributed to the decrease in the pre-
scription rate, particularly in the control male group. The effect of this labelling change would
lead to an overestimation of the decreased modelled rates of prescription during the post-
intervention period. Third, the observed prescription rates decreased again from 2012 to 2013.
The introduction of guidelines for the treatment of depression in 2012 advised not only of the
careful administration of antidepressants to patients with mild depression, but also regarding
the assessment of the risk of suicidality due to AD use [36]. These events may have amplified
the negative trend during the post-intervention period, particularly in adult males.
The causal relationship between depression and suicide has been well established; however,
other factors such as financial issues, unemployment, challenges in personal relationships, and
problems related to school have also been linked to suicidal behaviour [37,38]. The impact of
the labelling change on suicide rates may be limited due to the complexity of causal pathways
and interaction of suicide risk factors. Of note, the global financial crisis affected Japan’s econ-
omy in 2008, leading to increased unemployment in the young population (S3 Table).
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Consequently, job insecurity and economic worsening may have maintained the high rates of
suicide observed in the young population. In contrast, the decreasing rates of suicide among
adult males since 2009 were analysed, and the results demonstrated that interventions that
provide social supports and economic recovery contribute to improvements [39].
Strengths and limitations
The present study has several strengths. Firstly, it is appropriate for evaluating the effectiveness
of the labelling change as both process and outcome indicators are discussed [16]. Secondly,
the study design is ITS, which is the strongest quasi-experimental design to assess the impact
of an intervention in non-randomised settings [17]. Finally, the main study outcomes were to
ascertain the actual numbers and rates of prescription, which are less prone to reporting and
observer bias.
However, this study also has some limitations. Firstly, unemployment is a known risk factor
for depression and suicide [40]. However, the JMDC database did not contain data regarding
self-employed and unemployed individuals, who are at a relatively higher risk of depression
and suicide than corporate workers due to financial insecurity and psychosocial stress. Sec-
ondly, suicidal behaviour such as suicidal thoughts and self-harm have not been investigated
as surrogate outcomes due to the difficulty of obtaining such data from the claims database.
Thirdly, the enrolees in the JMDC database may differ slightly from the overall population in
Japan. The household income, extent of job insecurity and poverty, level of education, and liv-
ing conditions of enrolees in the JMDC database may differ from individuals covered by other
social health insurance schemes. Fourthly, the JMDC database contained potential measure-
ment biases such as coding inaccuracies and underreporting, which claims databases have by
their nature [14]. Therefore, the diagnosis of depression could be more than the actual number
given, because patients who did not need medication would not include the codes for depres-
sion if it was not required for reimbursement. Furthermore, the use of the segmented regres-
sion method has limitations, such as being affected by rapidly changing, time-varying
confounders, and long-term non-linear patterns [17,18]. In addition, reductions in prescrip-
tion at the individual level (i.e. reduction of dosage, number of concomitant ADs, and inter-
ruptions) were not investigated. Furthermore, severity of depression is not included in the
JMDC database; therefore, background changes in the overall severity of depression or differ-
ences in severity among drugs were not investigated. Regarding suicide rates, the impact of
other policies to prevent suicide cannot be excluded. This includes part of a national health
promotion policy named ‘Healthy Japan 21’ that allocated budget for suicide prevention in
2001, a new law called ‘General Principles of Suicide Prevention Policy’ in 2007, and a funding
programme for local governments.
Further studies are required to validate the reasons for the large shift observed in control
group males. To investigate the influencing factors, information on the specialities of prescrib-
ers can clarify whether drugs were prescribed by psychiatrists or other health workers and
whether they were prescribed before or after a diagnosis of depression. Qualitative studies tar-
geting physicians could also help to understand why they changed or did not change their pre-
scriptions. The gap between depression rates and prescription rates of all ADs widened after
the labelling change, particularly in the intervention group; however, it is not clear whether
patients who were not prescribed ADs remained untreated or received alternative therapies.
The long-term impact of AD prescription in young individuals on population health and sui-
cide rate should be assessed in future studies. To eliminate the uncertainty caused by using dif-
ferent databases, it would also be helpful to use alternative endpoints of suicides that can be
captured in the claims database such as emergency treatments for overdoses.
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Conclusions
Contrary to expectations, a negative level change in the prescription rate was clearly observed
in adults, particularly in males, compared with adolescents. A similar negative trend change
was observed in both groups. A possible explanation was that physicians have been reminded
about the association between medication and suicide risk by the revised precautions, and as a
result, prescribed ADs to adults more cautiously because this group has the highest suicide rate
in Japan. In contrast, there seems to have been no clear temporal association with suicide
rates.
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